Navigation Links
Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
Date:7/22/2010

CARY, N.C., July 22 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that it will host a conference call at 8:30 AM ET on Thursday, August 5, 2010, to discuss its financial results for the quarter and six months ended June 30, 2010.  Management will also provide an update on the Company's strategy, operations and product development pipeline.  Cornerstone intends to issue its financial results press release prior to the conference call.

To participate in the live conference call, please dial 800-561-2813 (U.S. callers) or 617-614-3529 (international callers), and provide passcode 12677542.  A live webcast of the call will also be available through the Investor Relations section of the Company's website.  Please allow extra time prior to the webcast to register, download and install any necessary audio software.

The webcast will be archived for 30 days, and a telephone replay of the call will be available for seven days, beginning at 11:30 AM ET on August 5, 2010, by dialing 888-286-8010 (U.S. callers) or 617-801-6888 (international callers), and providing passcode 28082122.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians, key retail pharmacies and hospitals with its specialty sales forces. The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales forces; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of preclinical studies and clinical trials with respect to our products under development, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 4, 2010 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Therapeutics Announces Management Change
2. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
3. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
4. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
5. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
6. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
7. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
8. Richard B. Brewer Joins Nile Therapeutics as Executive Chairman of the Board of Directors
9. Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
10. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
11. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Sweden , Mar 23, 2017 ... medicine company, today announced that the English version of the ... website www.neurovive.com .  ... About NeuroVive NeuroVive Pharmaceutical AB ... to the discovery and development of medicines that preserve mitochondrial ...
(Date:3/22/2017)... DUBLIN , Mar. 22, 2017 Research ... Care Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 10.9% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... 22, 2017 Under the impetus of ... market size increased year by year at the ... 2021, the market size will maintain the growth ... outnumber RMB140 billion in 2021, thanks to severe ... of biological agents and supporting policies. At ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... ... software solution, iCode Assurance, at HCCA’s 21st annual Compliance Institute on March 26-28 ... coding audit process for all medical chart types with a comprehensive set of ...
(Date:3/23/2017)... ... ... Journey Through Heaven”: the true-life account of a man who faced death and emerged ... for His people. “My Journey Through Heaven” is the creation of published author Earl ... grandchildren living and doing for God as best they can. , Published by Christian ...
(Date:3/23/2017)... ... ... simple and strong explanation of the God’s love. “More Corruption” is the creation of published ... to write a book about Him. , She says, “I’m fed up with mortals misjudging ... Lord God. They have not walked in my shoes and I know they never could ...
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma Solutions, the ... and consumer health products, today announced that it had won the ‘Clinical Supply ... the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award was presented ...
(Date:3/22/2017)... ... , ... Old School Labs™, makers of the best-selling Vintage line of natural ... Theophane, who trained with Floyd Mayweather, made his professional debut in London in 2003 ... impressive number of wins in contests in Britain, Germany and the U.S. , ...
Breaking Medicine News(10 mins):